![]() ![]() The Department of Pharmaceuticals’ recently released draft policy to catalyse R&D and innovation in the pharma and medtech sector (2021) aims to create strong academia-industry linkages, further promoting translational research, and manufacturing processes. The Government of India (GoI) lays strong emphasis on Research and Development (R&D) with the objective of developing novel technologies to venture into new therapies. India is not resting on its laurels in the vaccine segment. ![]() During the pandemic, by utilising the vibrant vaccine manufacturing ecosystem and adhering to the core Indian philosophy of Vasudhaiva Kutumbakam – the world is one family, India not only provided vaccines to 1.4 billion population but also catered to the world community with India supplying 242 million low-cost and high-quality vaccines to 101 countries. Biologicals and formulations (including vaccines) account for 77.5% of India’s pharmaceuticals’ export portfolio. ![]() India now supplies ~60% of the global demand for vaccines, with ~33% of vaccines supplied by Telangana’s life sciences ecosystem only. The growth has resulted in dominating the space with 65-70% of the vaccine requirements of the World Health Organization (WHO) being sourced from India. For instance, India accounts for nearly 90% of the global demand for the measles vaccine. Therefore, India has emerged as a dominant force in vaccines for diseases such as measles, Bacillus Calmette–Guérin (BCG), and Diphtheria, Tetanus and Pertussis (DPT). Over the last two decades, major pharmaceutical companies have invested heavily in increasing their manufacturing capabilities, catering to the huge global and domestic demand. The world became witness to India’s vaccine manufacturing prowess as India provided equitable access to resilient supply chains and logistics - further strengthening its position in the vaccine segment.Īlthough COVID-19 initiated the necessary boost to streamline and optimise manufacturing processes, India’s growth in the vaccine segment has been steady. India’s capabilities in the manufacturing of vaccines came to the fore during the COVID-19 pandemic. Great Places for Manufacturing in India.Production Linked Incentives (PLI) Schemes in India.Loan Guarantee Scheme for Covid Affected Sectors.Dadra and Nagar Haveli and Daman and Diu.Semiconductor and Display Manufacturing. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |